HBsAg loss in patients treated with peginterferon alfa-2a and adefovir is associated with SLC16A9 gene variation and lower plasma carnitine levels

Journal of Hepatology

Volumn 61, Issue 4, 2014, Pages 730-737

  Jansen, Louis ^a,b   De Niet, Annikki ^a,b   Stelma, Femke ^a,b   Van Iperen, Erik P A ^b,c   Van Dort, Karel A ^b   Plat Sinnige, Marjan J Tempelmans ^a,b   Takkenberg, R Bart ^a   Chin, Daniel J ^d   Zwinderman, A H Koos ^b   Lopatin, Uri ^e   Kootstra, Neeltje A ^b   Reesink, Hendrik W ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c Durrer Center for Cardiogenetic Research   (Netherlands)

^d Preclinical Development Pathology   (United States)

^e Assembly Pharmaceuticals   (United States)

Author keywords

Adefovir; Carnitine; Chronic hepatitis B; Genome wide association study; HBsAg loss; HBV specific T cells; Peginterferon alfa 2a; Response marker; SNP

Indexed keywords

ADEFOVIR DIPIVOXIL; CARNITINE; HEPATITIS B SURFACE ANTIGEN; HOST FACTOR; PEGINTERFERON ALPHA2A; ADEFOVIR; ADENINE; ALPHA INTERFERON; ANTIVIRUS AGENT; HEPATITIS B(E) ANTIGEN; MACROGOL DERIVATIVE; MCT9 PROTEIN, HUMAN; MONOCARBOXYLATE TRANSPORTER; PHOSPHONIC ACID DERIVATIVE; RECOMBINANT PROTEIN; VITAMIN B COMPLEX;

ADULT; ARTICLE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DNA POLYMORPHISM; ETHNIC DIFFERENCE; FEMALE; FOLLOW UP; GENE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IN VITRO STUDY; LYMPHOCYTE PROLIFERATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SLC16A9 GENE; TANDEM MASS SPECTROMETRY; TREATMENT OUTCOME; ANALOGS AND DERIVATIVES; BLOOD; DRUG COMBINATION; DRUG EFFECTS; GENETICS; HEPATITIS B, CHRONIC; IMMUNOLOGY; MIDDLE AGED; PHYSIOLOGY; PROGNOSIS;

ADENINE; ADULT; ANTIVIRAL AGENTS; CARNITINE; CD8-POSITIVE T-LYMPHOCYTES; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; MONOCARBOXYLIC ACID TRANSPORTERS; ORGANOPHOSPHONATES; POLYETHYLENE GLYCOLS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; RECOMBINANT PROTEINS; TREATMENT OUTCOME; VITAMIN B COMPLEX;

EID: 84919621941     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2014.05.004     Document Type: Article

References (35)

1. World Health Organization. Hepatitis B. World Health Organization fact sheet 204. World Health Organization; 2012.
2. Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol 2008; 48: 335-352.
3. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 167-185.
4. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661-662.
5. Lin SM, Yu ML, Lee CM, Chien RN, Sheen IS, Chu CM, et al. Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. J Hepatol 2007; 46: 45-52.
6. Janssen HL, van ZM, Senturk H, Zeuzem S, Akarca US, Cakaloglu Y, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005; 365: 123-129.
7. Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352: 2682-2695.
8. Marcellin P, Lau GK, Bonino F, Farci P, Hadziyannis S, Jin R, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004; 351: 1206-1217.
9. Buster EH, Flink HJ, Cakaloglu Y, Simon K, Trojan J, Tabak F, et al. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b. Gastroenterology 2008; 135: 459-467.
10. Manesis EK, Hadziyannis ES, Angelopoulou OP, Hadziyannis SJ. Prediction of treatment-related HBsAg loss in HBeAG-negative chronic hepatitis B: a clue from serum HBsAg levels. Antivir Ther 2007; 12: 73-82.
11. Takkenberg RB, Jansen L, de Niet A, Zaaijer HL, Weegink CJ, Terpstra V, et al. Baseline hepatitis B surface antigen (HBsAg) as predictor of sustained HBsAg loss in chronic hepatitis B patients treated with peginterferon alfa-2a and adefovir. Antivir Ther 2013; 18: 895-904.
12. Prokunina-Olsson L, Muchmore B, Tang W, Pfeiffer RM, Park H, Dickensheets H, et al. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet 2013; 45: 164-171.
13. de Niet A, Takkenberg RB, Benayed R, Riley-Gillis B, Weegink CJ, Zaaijer HL, et al. Genetic variation in IL28B and treatment outcome in HBeAg-positive and -negative chronic hepatitis B patients treated with Peg interferon alfa- 2a and adefovir. Scand J Gastroenterol 2012; 47: 475-481.
14. Holmes JA, Nguyen T, Ratnam D, Heerasing NM, Tehan JV, Bonanzinga S, et al. IL28B genotype is not useful for predicting treatment outcome in Asian chronic hepatitis B patients treated with pegylated-interferon-alpha. J Gastroenterol Hepatol 2013; 28: 861-866.
15. Lampertico P, Vigano M, Cheroni C, Facchetti F, Invernizzi F, Valveri V, et al. IL28B polymorphisms predict interferon-related hepatitis B surface antigen seroclearance in genotype D hepatitis B e antigen-negative patients with chronic hepatitis B. Hepatology 2013; 57: 890-896.
16. Sonneveld MJ, Wong VW, Woltman AM, Wong GL, Cakaloglu Y, Zeuzem S, et al. Polymorphisms near IL28B and serologic response to peginterferon in HBeAg-positive patients with chronic hepatitis B. Gastroenterology 2012; 142: 513-520.
17. Kamatani Y, Wattanapokayakit S, Ochi H, Kawaguchi T, Takahashi A, Hosono N, et al. A genome-wide association study identifies variants in the HLA-DP locus associated with chronic hepatitis B in Asians. Nat Genet 2009; 41: 591-595.
18. Kolz M, Johnson T, Sanna S, Teumer A, Vitart V, Perola M, et al. Meta-analysis of 28, 141 individuals identifies common variants within five new loci that influence uric acid concentrations. PLoS Genet 2009; 5: e1000504.
19. Vreken P, van Lint AE, Bootsma AH, Overmars H, Wanders RJ, van Gennip AH. Rapid diagnosis of organic acidemias and fatty-acid oxidation defects by quantitative electrospray tandem-MS acyl-carnitine analysis in plasma. Adv Exp Med Biol 1999; 466: 327-337.
20. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D. Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet 2006; 38: 904-909.
21. Cederblad G. Plasma carnitine and body composition. Clin Chim Acta 1976; 67: 207-212.
22. Flanagan JL, Simmons PA, Vehige J, Willcox MD, Garrett Q. Role of carnitine in disease. Nutr Metab (Lond) 2010; 7: 30.
23. Fortin G, Yurchenko K, Collette C, Rubio M, Villani AC, Bitton A, et al. Lcarnitine, a diet component and organic cation transporter OCTN ligand, displays immunosuppressive properties and abrogates intestinal inflammation. Clin Exp Immunol 2009; 156: 161-171.
24. Athanassakis I, Mouratidou M, Sakka P, Evangeliou A, Spilioti M, Vassiliadis S. L-carnitine modifies the humoral immune response in mice after in vitro or in vivo treatment. Int Immunopharmacol 2001; 1: 1813-1822.
25. Suhre K, Shin SY, Petersen AK, Mohney RP, Meredith D, Wagele B, et al. Human metabolic individuality in biomedical and pharmaceutical research. Nature 2011; 477: 54-60.
26. Bremer J. Carnitine-metabolism and functions. Physiol Rev 1983; 63: 1420-1480.
27. Engel AG, Rebouche CJ. Carnitine metabolism and inborn errors. J Inherit Metab Dis 1984; 7: 38-43.
28. Selimoglu MA, Yagci RV. Plasma and liver carnitine levels of children with chronic hepatitis B. J Clin Gastroenterol 2004; 38: 130-133.
29. Zhou L, Wang Q, Yin P, Xing W, Wu Z, Chen S, et al. Serum metabolomics reveals the deregulation of fatty acids metabolism in hepatocellular carcinoma and chronic liver diseases. Anal Bioanal Chem 2012; 403: 203-213.
30. Malaguarnera M, Restuccia S, Di Fazio I, Zoccolo AM, Ferlito L, Bentivegna P. Serum carnitine levels in chronic hepatitis C patients before and after lymphoblastoid interferon-alpha treatment. BioDrugs 1999; 12: 65-69.
31. Krahenbuhl S, Reichen J. Carnitine metabolism in patients with chronic liver disease. Hepatology 1997; 25: 148-153.
32. Eskandari GH, Kandemir O, Polat G, Tamer L, Ersoz G, Atik U. Serum Lcarnitine levels and lipoprotein compositions in chronic viral hepatitis patients. Clin Biochem 2001; 34: 431-433.
33. Wieland SF, Eustaquio A, Whitten-Bauer C, Boyd B, Chisari FV. Interferon prevents formation of replication-competent hepatitis B virus RNA-containing nucleocapsids. Proc Natl Acad Sci U S A 2005; 102: 9913-9917.
34. Thimme R, Dandri M. Dissecting the divergent effects of interferon-alpha on immune cells: time to rethink combination therapy in chronic hepatitis B? J Hepatol 2013; 58: 205-209.
35. Barditch-Crovo P, Toole J, Hendrix CW, Cundy KC, Ebeling D, Jaffe HS, et al. Anti-human immunodeficiency virus (HIV) activity, safety, and pharmacokinetics of adefovir dipivoxil (9-[2-(bis-pivaloyloxymethyl)-phosphonylmethoxyethyl] adenine) in HIV-infected patients. J Infect Dis 1997; 176: 406-413.